Skip to content

Advertisement

Pneumonia

What do you think about BMC? Take part in

Challenges and progress in childhood tuberculosis

© Flickr Marion Doss CC BY-SA 2.0Guest edited by Professor Ben Marais (University of Sydney, Australia), this series of articles provides an overview of the global child tuberculosis burden and examines issues such as diagnosis, advances in treatment, and novel vaccination approaches. The series aims to address the needs of researchers, clinicians and other individuals who require up-to-date information on this topic.


Pneumonia is pleased to be still accepting submissions for this thematic series.

Read more

Articles

  1. Content type: Commentary

      |  

    Authors: Ger T. Rijkers and Maria Rodriguez Gomez

View all articles
View all articles

Aims and scope

Pneumonia is the only journal to focus exclusively on pneumonia. Publishing original research, case reports, reviews, commentaries and correspondence, Pneumonia provides an international forum for the exchange of knowledge by scientists and clinicians involved in studying the etiology and pathogenesis of pneumonia, as well as its diagnosis, epidemiology, treatment and prevention. The journal's scope extends to research on lung infections and diagnosis, inflammation and immunity, microbial pathogenesis and viral-bacterial interactions.

Cutting-edge research, insightful reviews and dedication to the community make Pneumonia an essential resource for clinicians, researchers, respirologists and allied professionals involved with infectious diseases.

Pneumonia Cover

Pneumonia archive

Pneumonia transferred to BioMed Central from Griffith University ePress in January 2016.
The archive of the journal has been transferred to a new platform and all articles previously published in the journal can be accessed here.

Featured article: Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian Aboriginal population

New Content ItemThe 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to prevent invasive pneumococcal disease (IPD) in Western Australian (WA) Aboriginal people in 2001. PCV13 replaced PCV7 in July 2011, covering six additional pneumococcal serotypes; however, IPD rates remained high in Aboriginal people in WA. Upper respiratory tract pneumococcal carriage can precede IPD, and PCVs alter serotype distribution. This study describes the prevalence of overall carriage and that of individual serotypes in the WA Aboriginal population before and after the introduction of PCV13, along with epidemiological risk factors for carriage.

Read the article

Featured review: Atypical bacterial pneumonia in the HIV-infected population

New Content ItemHuman immunodeficiency virus (HIV)-infected individuals are more susceptible to respiratory tract infections by other infectious agents as their disease progresses to acquired immunodeficiency syndrome. Despite effective antiretroviral therapy, bacterial pneumonia remains a common cause of morbidity and mortality in the HIV-infected population. Due to the lack of available diagnostic strategies, the lack of consideration, and the declining immunity of the patient, HIV co-infections with atypical bacteria are currently believed to be underreported. This review aimed to highlight the current knowledge and gaps regarding atypical bacterial pneumonia in HIV. 

Read the article here

Latest Tweets

A note for authors

Pneumonia levies an article-processing charge for all articles accepted for publication. During the transition period for the journal, we are providing additional support for authors who do not have grant, institution, or other funding to cover the APC. If you do not have access to a funding source, please request a waiver stating the code PNEU17 on the payment page during submission.

Sign up to receive article alerts

Pneumonia is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.

Professor Allan Cripps

Editor profile

Professor Allan Cripps, Editor-in-Chief, is recognized internationally for his research in the field of mucosal immunology. Much of this work has been directed towards mucosal immunization against a range of bacterial pathogens, particularly those of the respiratory tract. In 2015 he was awarded an Officer of the Order of Australia in recognition of his contributions to mucosal immunization, public health and higher education. He has published extensively in the peer-reviewed literature, presented his research findings at numerous international scientific and medical conferences and has been the recipient of a large number of competitive government and industry research grants. In addition, Professor Cripps has a significant patent portfolio in the fields of diagnostics and vaccine protein antigens. Professor Cripps joined Griffith University in May 2003 where he was responsible for the establishment of the University’s School of Medicine and Health Faculty (2003 to 2016). He is currently a research professor with the School of Medicine at Griffith University. 

Advertisement

2016 Journal Metrics

  • Speed
    19 days from submission to first decision
    13 days from acceptance to publication

    Usage 
    19,655 downloads
    498.5 Usage Factor

    Social Media Impact
    15 mentions

Advertisement